Erythropoietin resistance in the treatment of the anemia of chronic renal failure

Seminars in Dialysis

Volumn 19, Issue 4, 2006, Pages 273-278

  Priyadarshi, Anumeet ^a   Shapiro, Joseph I ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY FAILURE; DRUG RESISTANCE; HUMAN; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA; DRUG RESISTANCE; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 33746265282     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00172.x     Document Type: Review

References (83)

1. Greer JW, Milam RA, Eggers PW: Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98. Health Care Financ Rev 20(3):55-62, 1999
2. Jacobson LO, Goldwasser E, Fried W, Plzak L: Role of the kidney in erythropoiesis. Nature 179:633-634, 1957
3. Miyake T, Kung CK-H, Goldwasser E: Purification of human erythropoietin. J Biol Chem 252:5558-5564, 1977
4. Lai PH, Everett R, Wang FF, Arakawa T, Goldwasser E: Structural characterization of human erythropoietin. J Biol Chem 261:3116-3121, 1986
5. Priyadarshi A, Periysamy S, Burke TJ, Britton SL, Malhotra D, Shapiro JI: Effects of reduction of renal mass on renal oxygen tension and erythropoietin (EPO) production in the rat. Kidney Int 61:542-546, 2002
6. Eschbach JW: Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol 13:1412-1414, 2002
7. NKF-DOQI Clinical Practice Guidelines for Anemia of Chronic Renal Failure: update 2000. IV. Administration of epoetin. Am J Kidney Dis 37(suppl 1):S182-S238, 2001
8. Hutchinson F, Jones WJ: A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Am J Kidney Dis 29:651-657, 1997
9. Loge JP, Lange RD, Moore CV: Characterization of the anemia associated with chronic renal insufficiency. Am J Med 24:4-18, 1958
10. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
11. Erslev AJ, Besarb A: Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 51:662-630, 1997
12. Eschbach JW: Iron requirements in erythropoietin therapy. Best Pract Res Clin Hematol 18:347-361, 2005
13. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26:292-299, 1995
14. Danielson B: r-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 10:69-73, 1995
15. Drueke TB: r-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 10:62-68, 1995
16. Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29:565-568, 1997
17. Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33:63-72, 1999
18. Eschbach JW, Funk DD, Adamson J, Kuhn K, Scribner BH, Finch CA: Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 276:653-658, 1967
19. Eschbach JW: The future of r-HuEPO. Nephrol Dial Transplant 10(suppl 2):96-109, 1995
20. Griffing GT, Melby JC: Enalapril (MK-420) and the white cell count and hematocrit. Lancet 1:1361, 1982
21. Fyhrquist F, Karppinen K, Honkannen T, Saijonmaa O, Rosenlof K: High serum-erythropoietin levels are normalised during treatment of congestive heart failure with enalapril. J Intern Med 226:257-260, 1989
22. Kamper AL, Nielson OJ: Effect of enalapril on hemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 50:611-618, 1990
23. Hirakata H, Onayama K, Iseki K, Kumagai H, Fujimi S, Omae T: Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 4:355-360, 1984
24. Yoshida A, Morozumi K, Suganuma T, Aoki J, Sugito K, Nakamura S, Ikeda M, Oikawa T, Fujinami T, Kawahara H: Angiotensin-converting enzyme inhibitor and anemia in a patient undergoing hemodialysis. Nephron 59:334-335, 1991
25. Hirakata H, Onayama K, Hori K, Fujishima M: Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol 26:27-32, 1986
26. Conlon PJ, Albers F, Butterly D, Schwab SJ: ACE inhibitors do not affect erythropoietin efficacy in hemodialysis patients. Nephrol Dial Transplant 9:1358, 1994
27. Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL: Angiotensin- converting enzyme inhibitor therapy in chronic hemodialysis patients any evidence of erythropoietin resistance? Am J Kidney Dis 4:535-540, 1996
28. Beckingham U, Woodrow G, Hinwood M, Rigg KM, Morgan AG, Burden RP, Broughton-Pipkin F: A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrol Dial Transplant 10:2316-2320, 1995
29. Nakao K, Shirakura T, Azuma M, Maekawa T: Study of erythroid erythropoietic action of angiotensin II. Blood 29:754-760, 1967
30. Gould AB, Goodman SA, DeWolf R, Onesti G, Swartz C: Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med 96:523-534, 1980
31. Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ: Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 26:495-500, 1995
32. Islam MS, Bourbigot B, Codet JP, Songy B, Fournier G, Cledes J: Captopril induces correction of postrenal transplant erythremia. Transplant Int 3:222-225, 1990
33. Rostaing L, Demur C, Huyn A, Durand D, Lloveras JJ, Suc JM: Erythrocytosis after renal transplant study of erythroid progenitors and response to enalapril. Transplant Proc 26:280-281, 1994
34. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
35. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171-175, 1993
36. Yuan B, Klein MH, Contiguglia RS, Mishell JL, Seligman PA, Miller NL, Molitoris BA, Alfrey AC, Shapiro JI: The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population. Ren Fail 11:91-96, 1989
37. Vittori D, Garbossa G, Lafourcade C, Perez G, Nesse A: Human erythroid cells are affected by aluminium. Alteration of membrane band 3 protein. Biochim Biophys Acta 1558:142-150, 2002
38. Kaiser L, Schwartz KA: Aluminum-induced anemia. Am J Kidney Dis 6:348-352, 1985
39. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE: The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 6:342-345, 1991
40. Grutzmacher P, Ehmer B, Messinger D, Kulbe KD, Scigalla P: Effect of aluminum overload on the bone marrow response to recombinant human erythropoietin. Contrib Nephrol 76:315-323, 1989
41. Di Iorio B, Guastaferro P, Bellizzi V: Relationship between resistance to erythropoietin and high anomalous hemoglobin levels in hemodialysis patients with beta-thalassemia minor. Blood Purif 21:376-380, 2003
42. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. BMJ 295:1017-1020, 1987
43. Tomson CR, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J: Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 7:817-821, 1992
44. Steinberg MH: Erythropoietin for anemia of renal failure in sickle cell disease [letter]. N Engl J Med 324:1369-1370, 1991
45. Roger SE, Macdougall IC, Thuraisingham RC, Raine AEG: Erythropoietin in anemia of renal failure in sickle cell disease [letter]. N Engl J Med 325:1175-1176, 1991
46. Uno K, Hisasue Y: Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy? Clin Nephrol 38:290-292, 1992
47. Zachee P, Chew SL, Daelemans R, Lins RL: Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment. Am J Nephrol 12:188-191, 1992
48. Klemm A, Sperschneider H, Lauterbach H, Stein G: Is folate and vitamin B12 supplementation necessary in chronic hemodialysis patients with EPO treatment? [letter]. Clin Nephrol 42:343-345, 1994
49. Caillette A, Barreto S, Gimenez E, Labeeuw M, Zech P: Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis? Clin Nephrol 40:176-178, 1993
50. Siimes MA, Ronnholm KAR, Antikainen M, Holmberg C: Factors limiting the erythropoietin response in rapidly growing infants with congenital nephrosis on a peritoneal dialysis regimen after nephrectomy. J Pediatr 120:44-48, 1992
51. Evers J: Cardiac hemolysis and anemia refractory to erythropoietin: on anemia in dialysis patients [letter]. Nephron 71:108, 1995
52. Kitamura Y, Satoh K, Satoh T, Takita M, Matsuura A: Effect of L-carnitine on erythroid colony formation in mouse bone marrow cells. Nephrol Dial Transplant 20:981-984, 2005
53. Hurot JM, Cucherat M, Haugh M, Fouque D: Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 13:708-714, 2002
54. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl. J Med 334:420-425, 1996
55. Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R: Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 16:111-114, 2001
56. Lindsay RM, Daily/Nocturnal Dialysis Study Group: The London, Ontario, Daily/Nocturnal Hemodialysis Study. Semin Dial 17:85-91, 2004
57. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S: Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 16:2778-2788, 2005
58. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996
59. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 79:299-305, 1998
60. Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433-439, 1995
61. Chang CH, Chang CC, Chiang SS: Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 57:136-141, 2002
62. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530-538, 2000
63. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
64. Sunder-Plassmann G, Horl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
65. Taylor JE, Peat N, Porter C, Morgan AG: Regular low-dose intravenous iron therapy improves response to erythropoietin in hemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996
66. Ahsan N: Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 9:664-668, 1998
67. Bridges KR, Hoffman KE: The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem 261:14273-14277, 1986
68. Lipschitz DA, Bothwell TH, Seftel HC, Wapnick AA, Charlton RW: The role of ascorbic acid in the metabolism of storage iron. Br J Hematol 20:155-163, 1971
69. Deicher R, Ziai F, Habicht A, Bieglmayer C, Schillinger M, Horl WH: Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis. Nephrol Dial Transplant 19:2319-2324, 2004
70. Descombes E, Hanck AB, Fellay G: Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 43:1319-1328, 1993
71. Pru C, Eaton J, Kjellstrand C: Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron 39:112-116, 1985
72. Balcke P, Schmidt P, Zazgornik J, Kopsa H, Haubenstock A: Ascorbic acid aggravates secondary hyperoxalemia in patients on chronic hemodialysis. Ann Intern Med 101:344-345, 1984
73. Canavese C, Petrarulo M, Massarenti P, Berutti S, Fenoglio R, Pauletto D, Lanfranco G, Bergamo D, Sandri L, Marangella M: Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 45:540-549, 2005
74. Eknoyan G, Latos DL, Lindberg J: Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 41:868-876, 2003
75. Golper TA, Goral S, Becker BN, Langman CB: L-camitine treatment of anemia. Am J Kidney Dis 41:S27-S34, 2003
76. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ: Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 17:29-33, 1991
77. Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michael B, Burke JF: A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 30:495-500, 1997
78. Berns JS, Rudnick MR, Cohen RM: A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 37:264-267, 1992
79. Sheashaa H, Abdel-Razek W, El-Husseini A, Selim A, Hassan N, Abbas T, El-Askalani H, Sobh M: Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron Clin Pract 99:102-106, 2005
80. Navarro JF, Mora C, Garcia J, Rivero A, Macia M, Gallego E, Mendez ML, Chahin J: Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol 33:121-125, 1999
81. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC: Pentoxifylline improves hemoglobin levels in patients with erythropoietin- resistant anemia in renal failure. J Am Soc Nephrol 15:1877-1882, 2004
82. Benbernou N, Esnault S, Potron G, Guenounou M: Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol 25(suppl 2):S75-S79, 1995
83. Sirken G, Kung SC, Raja R: Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 49:422-425, 2003